Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease
This study found that tau PET is valuable for both prognostic and real-time tracking of disease progression. Plasma p-tau217 predicts cognitive changes prior to overt cognitive impairment and can efficiently guide participant selection. Imaging-based tau measures may enhance detection of disease-modifying effects and refine therapeutic targets in future Alzheimer disease trials.
Authors
- Reisa Anne Sperling (ORCID: https://orcid.org/0000-0003-1535-6133)
- Oliver Langford (ORCID: https://orcid.org/0009-0006-8951-1326)
- Adam L. Boxer (ORCID: https://orcid.org/0000-0002-1215-5064)
- Vincent M. Caruso (ORCID: https://orcid.org/0000-0002-8738-2552)
- Michael Donohue (ORCID: https://orcid.org/0000-0001-6026-2238)
- Niklas Mattsson (ORCID: https://orcid.org/0000-0002-8885-7724)
- Antoine Leuzy (ORCID: https://orcid.org/0000-0003-4542-7879)
- Philip S. Insel (ORCID: https://orcid.org/0000-0002-6270-5490)
- Elizabeth C. Mormino (ORCID: https://orcid.org/0000-0002-4542-6537)
- Christina B. Young (ORCID: https://orcid.org/0000-0001-9535-2137)
- Paul Aisen
Institutions
- University of Southern California (US)
- Alzheimer's Association (US)
- Brigham and Women's Hospital (US)
- Autism Research Institute (US)
- University of California, San Francisco (US)
- Neurosciences Institute (US)
- Lund University (SE)
- Massachusetts General Hospital (US)
- Skåne University Hospital (SE)
- Center for Pain and the Brain (US)
- Banner Alzheimer’s Institute
- Stanford University (US)
Publication Details
- Journal
- JAMA Neurology
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1001/jamaneurol.2025.2974
- Citations
- 12
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 17.65